Intracellular doppler imaging clinical trials in personalized cancer care

David D. Nolte, Zhe Li, Honggu Choi, Michael Childress, John Turek, Shadia Jalal

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Clinical trials of biodynamic digital holography in human esophageal cancer and canine B-cell lymphoma, performed within 24 hours of biopsy acquisition, have an accuracy of 90% identifying patients resistant to their prescribed chemotherapy. Translation of this biomedical optical technology to clinical laboratory services has the potential to transform personalized cancer care.

Original languageEnglish (US)
Title of host publicationCLEO
Subtitle of host publicationApplications and Technology, CLEO_AT 2018
PublisherOSA - The Optical Society
VolumePart F92-CLEO_AT 2018
ISBN (Electronic)9781557528209
DOIs
StatePublished - Jan 1 2018
EventCLEO: Applications and Technology, CLEO_AT 2018 - San Jose, United States
Duration: May 13 2018May 18 2018

Other

OtherCLEO: Applications and Technology, CLEO_AT 2018
CountryUnited States
CitySan Jose
Period5/13/185/18/18

Fingerprint

Clinical laboratories
Chemotherapy
Biopsy
Holography
Medical imaging
Cells

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Mechanics of Materials

Cite this

Nolte, D. D., Li, Z., Choi, H., Childress, M., Turek, J., & Jalal, S. (2018). Intracellular doppler imaging clinical trials in personalized cancer care. In CLEO: Applications and Technology, CLEO_AT 2018 (Vol. Part F92-CLEO_AT 2018). OSA - The Optical Society. https://doi.org/10.1364/CLEO_AT.2018.ATu4J.6

Intracellular doppler imaging clinical trials in personalized cancer care. / Nolte, David D.; Li, Zhe; Choi, Honggu; Childress, Michael; Turek, John; Jalal, Shadia.

CLEO: Applications and Technology, CLEO_AT 2018. Vol. Part F92-CLEO_AT 2018 OSA - The Optical Society, 2018.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Nolte, DD, Li, Z, Choi, H, Childress, M, Turek, J & Jalal, S 2018, Intracellular doppler imaging clinical trials in personalized cancer care. in CLEO: Applications and Technology, CLEO_AT 2018. vol. Part F92-CLEO_AT 2018, OSA - The Optical Society, CLEO: Applications and Technology, CLEO_AT 2018, San Jose, United States, 5/13/18. https://doi.org/10.1364/CLEO_AT.2018.ATu4J.6
Nolte DD, Li Z, Choi H, Childress M, Turek J, Jalal S. Intracellular doppler imaging clinical trials in personalized cancer care. In CLEO: Applications and Technology, CLEO_AT 2018. Vol. Part F92-CLEO_AT 2018. OSA - The Optical Society. 2018 https://doi.org/10.1364/CLEO_AT.2018.ATu4J.6
Nolte, David D. ; Li, Zhe ; Choi, Honggu ; Childress, Michael ; Turek, John ; Jalal, Shadia. / Intracellular doppler imaging clinical trials in personalized cancer care. CLEO: Applications and Technology, CLEO_AT 2018. Vol. Part F92-CLEO_AT 2018 OSA - The Optical Society, 2018.
@inproceedings{cfb280bfb68e4924915066cc3c2b9098,
title = "Intracellular doppler imaging clinical trials in personalized cancer care",
abstract = "Clinical trials of biodynamic digital holography in human esophageal cancer and canine B-cell lymphoma, performed within 24 hours of biopsy acquisition, have an accuracy of 90{\%} identifying patients resistant to their prescribed chemotherapy. Translation of this biomedical optical technology to clinical laboratory services has the potential to transform personalized cancer care.",
author = "Nolte, {David D.} and Zhe Li and Honggu Choi and Michael Childress and John Turek and Shadia Jalal",
year = "2018",
month = "1",
day = "1",
doi = "10.1364/CLEO_AT.2018.ATu4J.6",
language = "English (US)",
volume = "Part F92-CLEO_AT 2018",
booktitle = "CLEO",
publisher = "OSA - The Optical Society",

}

TY - GEN

T1 - Intracellular doppler imaging clinical trials in personalized cancer care

AU - Nolte, David D.

AU - Li, Zhe

AU - Choi, Honggu

AU - Childress, Michael

AU - Turek, John

AU - Jalal, Shadia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Clinical trials of biodynamic digital holography in human esophageal cancer and canine B-cell lymphoma, performed within 24 hours of biopsy acquisition, have an accuracy of 90% identifying patients resistant to their prescribed chemotherapy. Translation of this biomedical optical technology to clinical laboratory services has the potential to transform personalized cancer care.

AB - Clinical trials of biodynamic digital holography in human esophageal cancer and canine B-cell lymphoma, performed within 24 hours of biopsy acquisition, have an accuracy of 90% identifying patients resistant to their prescribed chemotherapy. Translation of this biomedical optical technology to clinical laboratory services has the potential to transform personalized cancer care.

UR - http://www.scopus.com/inward/record.url?scp=85049130682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049130682&partnerID=8YFLogxK

U2 - 10.1364/CLEO_AT.2018.ATu4J.6

DO - 10.1364/CLEO_AT.2018.ATu4J.6

M3 - Conference contribution

VL - Part F92-CLEO_AT 2018

BT - CLEO

PB - OSA - The Optical Society

ER -